SIC
XENE icon

SJS Investment Consulting’s Xenon Pharmaceuticals XENE Stock Holding History

SJS Investment Consulting’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5
Closed -$216 – 1713
2024
Q1 		$216 Hold
5
– – ﹤0.01% 1472
2023
Q4 		$231 Buy
5
+2
+67% +$71 ﹤0.01% 1432
2023
Q3 		$103 Buy
3
+1
+50% +$37 ﹤0.01% 1539
2023
Q2 		$77 Buy
+2
New +$80 ﹤0.01% 1539

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SJS Investment Consulting's XENE Position: Q2 2024 in Review

SJS Investment Consulting sold out of Xenon Pharmaceuticals (XENE) in Q2 2024, closing a stake of 5 shares — an estimated $216 sold.

SJS Investment Consulting first reported a position in XENE in Q2 2023 and held it in 4 quarters. The position peaked at $231 in Q4 2023. 213 funds tracked by Wall St. Rank hold XENE as of Q2 2024.

  • SJS Investment Consulting reported no remaining Xenon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • SJS Investment Consulting sold 5 Xenon Pharmaceuticals shares in Q2 2024, an estimated $216.
  • SJS Investment Consulting first reported a position in Xenon Pharmaceuticals in Q2 2023 and held it in 4 quarters.
  • SJS Investment Consulting's Xenon Pharmaceuticals position peaked at $231 in Q4 2023.
  • 213 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2024.

Based on SJS Investment Consulting's 13F filing for Q2 2024, filed 16 Jul 2024.